Inotiv (NOTV) Investor presentation summary

Investment highlights

• Leading CRO serving small and midsized biopharma and medical device companies, with a $25B addressable market and vertically integrated DSA and RMS segments.

• Focus on high-science, high-service delivery, optimizing sites for cost savings and improved logistics to enhance client satisfaction.

• Engaged financial advisors to explore debt refinancing alternatives.

Industry overview

• Global discovery and preclinical CRO market projected to grow at 9.1% CAGR from 2023 to 2033.

• Emerging biopharma companies drive 85% of early drug development, with SMIDS increasing R&D spend share.

• Innovation continues to fuel the rise of new small biotech companies.

Strategic evolution

• Phase I (2018–2023): Growth through M&A and organic investments to build a full-service CRO.

• Phase II (2023–2025): Integration and optimization for unified client experience and operational efficiency.

• Phase III (2025 onward): Margin expansion via operating leverage, cost management, and continued growth.